A novel small molecule agonist of integrin CD11b/CD18 (also known as Mac-1). LA1 increases the extent of CD11b/CD18-dependent cell adhesion of transfected cells and of primary human and mouse neutrophils, which results in decreased chemotaxis and transendothelial migration. LA1 also decreases leukocyte recruitment and reduced arterial narrowing after injury in rats. In addition, compared to a known integrin antagonist IMB-10, LA1 better preserves kidney function in a mouse model of experimental nephritis.